Amgen Stock Jumps 3.36% on Positive Phase 3 Results for Dazodalibep

Amgen stock closed at $406.37 on September 22, 2026, after gaining 3.36% compared to the prior close. The surge in price followed the announcement of positive Phase 3 results for dazodalibep in Sjogren's disease. According to JKN, the company added $13.21 during the session.

The trial enrolled approximately 621 patients and showed improvement in systemic disease activity at Week 48. Amgen plans to present detailed data at an upcoming medical meeting. The next trading session will likely focus on clinical-data milestones, including the completion of the OASIZ 303 study in the fourth quarter of 2026.